Market Cap : 2.64 B | Enterprise Value : 2.2 B | PE Ratio : 26.45 | PB Ratio : 5.03 |
---|
NAS:CORT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:CORT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Corcept Therapeutics's enterprise value is $2,200.2 Mil. Corcept Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was $130.4 Mil. Therefore, Corcept Therapeutics's EV-to-EBITDA for today is 16.87.
During the past 13 years, the highest EV-to-EBITDA of Corcept Therapeutics was 429.79. The lowest was -167.98. And the median was 11.66.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2021-04-12), Corcept Therapeutics's stock price is $22.430000. Corcept Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was $0.85. Therefore, Corcept Therapeutics's PE Ratio for today is 26.39.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.
* The bar in red indicates where Corcept Therapeutics's EV-to-EBITDA falls into.
Corcept Therapeutics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 2200.211 | / | 130.439 | |
= | 16.87 |
Corcept Therapeutics's current Enterprise Value is $2,200.2 Mil.
Corcept Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2020 was 38.313 (Mar. 2020 ) + 35.771 (Jun. 2020 ) + 25.283 (Sep. 2020 ) + 31.072 (Dec. 2020 ) = $130.4 Mil.
* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Corcept Therapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 22.430000 | / | 0.85 | |
= | 26.39 |
Corcept Therapeutics's share price for today is $22.430000.
Corcept Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2020 was 0.25 (Mar. 2020 ) + 0.23 (Jun. 2020 ) + 0.17 (Sep. 2020 ) + 0.2 (Dec. 2020 ) = $0.85.
* All numbers are in millions except for per share data and ratio. All numbers are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
No Headline